Identification of a Novel Allosteric Inhibitory Site on Tryptophan Hydroxylase 1 Enabling Unprecedented Selectivity Over all Related Hydroxylases

Mike Petrassi¹, Rob Barber², Celine Be³, Sarah Beach², Brian Cox², Anne-Marie D’Souza², Nick Duggan N, Martin Hussey², Roy Fox², Peter Hunt², Gabor Jarai², Takatoshi Kosaka², Paul Oakley², Viral Patel², Neil Press³, David Rowlands², Clemens Scheufler³, Oliver Schmidt³, Honnappa Srinivas³, Mary Turner¹, Rob Turner², John Westwick², Alison Wolfreys², Nuzhat Pathan¹, Simon Watson² and Matthew Thomas²,4*

¹ Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA, ² Respiratory Disease Area, Novartis Institutes for BioMedical Research, Horsham, UK, ³ Novartis Institutes for BioMedical Research, Basel, Switzerland, ⁴ Translational Biology, Respiratory, Inflammation and Autoimmunity IMED, AstraZeneca, Gothenburg, Sweden

Pulmonary arterial hypertension (PAH) has demonstrated multi-serotonin receptor dependent pathologies, characterized by increased tone (5-HT₁B receptor) and complex lesions (SERT, 5-HT₁B, 5-HT₂B receptors) of the pulmonary vasculature together with right ventricular hypertrophy, ischemia and fibrosis (5-HT₂B receptor). Selective inhibitors of individual signaling elements – SERT, 5-HT₂A, 5HT₂B, and combined 5-HT₂A/B receptors, have all been tested clinically and failed. Thus, inhibition of tryptophan hydroxylase 1 (TPH1), the rate limiting step in 5-HT synthesis, has been suggested as a more broad, and thereby more effective, mode of 5-HT inhibition. However, selectivity over non-pathogenic enzyme family members, TPH2, phenylalanine hydroxylase, and tyrosine hydroxylase has hampered therapeutic development. Here we describe the site/sequence, biochemical, and biophysical characterization of a novel allosteric site on TPH1 through which selectivity over TPH2 and related aromatic amino acid hydroxylases is achieved. We demonstrate the mechanism of action by which novel compounds selectively inhibit TPH1 using surface plasma resonance and enzyme competition assays with both tryptophan ligand and BH4 co-factor. We demonstrate 15-fold greater potency within a human carcinoid cell line versus the most potent known TPH1/2 non-specific inhibitor. Lastly, we detail a novel canine in vivo system utilized to determine effective biologic inhibition of newly synthesized 5-HT. These findings are the first to demonstrate TPH1-selective inhibition and may pave the way to a truly effective means to reduce pathologic 5-HT and thereby treat complex remodeling diseases such as PAH.

Keywords: serotonin, tryptophan, allosteric binding, pulmonary arterial hypertension

Abbreviations: 5-HT, 5-hydroxytryptamine; BH4, tetrahydrobiopterin; HTAB, hexadecyltrimethylammonium bromide; PAH, pulmonary arterial hypertension; pCPA, p-chlorophenylalanine; PH, phenylalanine hydroxylase; SERT, serotonin transporter; TPH, tryptophan hydroxylase; TH, tyrosine hydroxylase.
INTRODUCTION

Serotonin (5-HT) has 15 receptors (5-HTR) divided into seven families, whose wide distribution and function both peripherally and within the central nervous system indicate the complexity of this signaling system (Berger et al., 2009). Despite this complexity, effective therapeutics of serotonin signaling have been developed; SERT antagonists for the treatment of depression (Stahl et al., 2013); 5-HT₁ receptor isoform agonists for migraine headaches (Derry et al., 2014); 5-HT₂A receptor inhibitors as atypical anti-psychotics (Werner and Covenas, 2014); 5-HT₃ receptor inhibitors for the treatment of chemotherapy-induced vomiting and irritable bowel syndrome (Cremolini et al., 2012). However, diseases characterized by more complex pathophysiology involving multiple elements of the 5-HT signaling cascade have failed to respond to selective receptor therapies.

Pulmonary arterial hypertension has demonstrated multi-serotonin receptor pathologies, characterized by increased tone (5-HT₁B receptor) and complex lesions (SERT, 5-HT₁B, 5-HT₂B receptors) of the pulmonary vasculature together with right ventricular hypertrophy, ischemia and fibrosis (5-HT₂B receptor) (Thomas et al., 2013). Inhibitors of SERT (Shah et al., 2009), 5-HT₂A (Frishman et al., 1995), 5-HT₂B (Tomillero and Moral, 2008), and combined 5-HTR₂A/B (Dumitrascu et al., 2011) receptors have all been tested clinically and failed. Furthermore, carcinoid syndrome, in which carcinoid tumor metastases in the lung over-produce 5-HT (avoiding hepatic degradation) presents as a broad array of symptoms through several 5-HT receptors – nausea/vomiting, diarrhea (5-HT₃ receptor), bronchoconstriction (5-HT₁B, 5-HT₂B receptors), right heart fibrosis (5-HT₂B receptor) (Druce et al., 2009).

As with pulmonary endothelium in PAH, carcinoid tumors produce large amounts of 5-HT through the over-expression TPH1 – the rate limiting step in 5-HT synthesis (Lovenberg et al., 1967). Pre-clinical data in models of PAH using either siRNA blockade of TPH1 or therapeutic inhibition via the low molecular weight compound pCPA has shown profound effects on both vasoactive and remodeling disease indices (Morecroft et al., 2012). However, the therapeutic potential of pCPA is limited by additional activity on other aromatic amino acid hydroxylases (tyrosine and PH) and the alternative TPH isoform TPH2. The two TPH isoforms differ in distribution, with TPH1 responsible for peripheral 5-HT synthesis whereas TPH2 predominates in the brainstem, and is thus responsible for the majority of behavior-related 5-HT production and subsequent signaling (5-HT does not cross the blood brain barrier) (Walther et al., 2003). Early clinical data in carcinoid syndrome using pCPA revealed the liabilities of non-selective TPH inhibition, where TPH2 inhibition has been retrospectively attributed to psychosis observed in some patients (Engelman et al., 1967). More recent molecules such as Telotristat etiprate, which more potently inhibits TPH1/2 than pCPA, with better selectivity over related aromatic amino acid hydroxylases, have demonstrated efficacy in carcinoid syndrome trials showing some symptomatic improvements and good tolerability (Kulke et al., 2014). The distribution and activity of telotristat etiprate is predominantly gut restricted (Shi et al., 2008; Kim et al., 2015) - the principal site of physiologic TPH1 activity/5-HT production – avoiding the adverse effects of TPH2-mediated 5-HT production in the CNS and consequent psychiatric toxicity. However, the efficacy of such a therapeutic strategy is limited in diseases where the principal site of pathologic 5-HT production is distal to the gut, such as pulmonary endothelium in PAH or lung metastases in carcinoid syndrome.

Thus it is clear that there is a need for peripherally acting inhibitors of TPH1 with selectivity over TPH2. The high degree of homology between the isoforms (71% amino acid identity) and identical orthosteric site binding residues (Walther and Bader, 2003; Walther et al., 2003) make gaining selectivity an extreme medicinal chemistry challenge. Platelet storage of synthesized 5-HT also represents a challenge for biology in demonstrating inhibition of TPH1 activity in vivo. Here we describe the biochemical and biophysical characterization of a novel allosteric site on TPH1 through which selectivity over TPH2 is achieved and demonstrate the mechanism of action of compound inhibition. We describe the evolving potency and selectivity of TPH1-selective compounds, which originate from a novel high-throughput proximity assay screen. Furthermore, we detail novel in vitro and in vivo systems utilized to determine effective biologic inhibition of newly synthesized 5-HT by a novel antagonist series.

MATERIALS AND METHODS

In Vitro TPH Activity Assays

Human TPH-1 and Human TPH-2 enzyme assays were carried out at room temperature with atmospheric oxygen in a volume of 25 μL. A base buffer of 40 mM HEPES pH 7.0, 200 mM ammonium sulfate was made and stored at 4°C. On the day of assay, final concentrations of 10 μM iron ammonium sulfate, 0.1 mg mL⁻¹ BSA, 25 μg mL⁻¹ catalase, and 0.04% Chaps were added and designated as enzyme buffer. Substrate buffer was made the same way but for the addition of a final concentration of 10 mM DTT. Enzymes were diluted as follows: 1.25x = 12.5 nM TPH1 (Final = 10 nM) or 1.25x = 37.5 nM TPH2 (Final = 30 nM) in enzyme buffer. Substrates were diluted as follows: 5x = 200 μM (6R)-5,6,7,8-Tetrahydrobipiperidine dihydrochloride (BH₄) (Final = 40 μM) and 5x = 100 μM Tryptophan (Final = 20 μM) in substrate buffer. Compounds were serially diluted 1:1 in DMSO to 50x = 500 μM (Final = 10 μM). Assays were performed in GNF Custom Greiner Black 384-well plates. Compounds were added at 0.5 μL per well. Enzymes were added at 20 μL per well. Compounds and enzymes were pre-incubated 15 min at room temperature. Substrates were added at 5 μL per well to initiate the reaction. The plates were covered and incubated at room temperature: 30 min for TPH1 and 60 min for TPH2. The reactions were quenched with the addition of 25 μL 30% sulfuric acid. The plates were read immediately with a PerkinElmer Envision reader at excitation = 280 and emission = 535.
**Protein Preparation and X-ray Crystallography**

*Escherichia coli* BL21 Rosetta (DE3) cells harboring a plasmid encoding human TPH1 (amino acid residues 103–413 or residues 104–394) with N-terminal His6-tag were grown in a bioreactor in auto induction medium. The constructs TPH1 (103–413) and TPH1 (104–394) were used for x-ray crystallization and SPR experiments, respectively (equivalent biochemical activity demonstrated – data not shown). Frozen cell pellets were homogenized in 50 mM Tris-HCl (pH 8.0), 400 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine (TCEP), 5% glycerol, 0.1% 3-([3-cholamidopropyl) dimethylammonio]-1-propanesulfonate and the protease inhibitor cocktail complete/EDTA free (Roche) and cells were lysed with a microfluidizer. The protein was purified by Ni-NTA (Qiagen). The His6-tag was removed with HRV 3C protease cleavage followed by size exclusion chromatography (Superdex SPX200/16/60; GE Healthcare), using MES 25 mM, pH 6, NaCl 100 mM, Glycerol 5%, Methionine 3 mM, TCEP 2 mM as elution buffer. For crystallization purposes, the protein was concentrated to 10 mg ml\(^{-1}\). The resulting protein was estimated to be >95% pure and homogeneous by SDS-PAGE and reverse phase HPLC. The identity of the protein was further confirmed by N-terminal sequencing and mass spectrometry (Q-Tof, Micromass, Waters). Structural location diagrams were generated using Molsoft ICMPro modeling tool. Protein sequence alignment was enabled by RCSB protein databank and EMBL Cluster Omega analysis.

**Biacore**

Biosensor experiments were performed on a Biacore T100 instrument (GE Healthcare). Biotinylation and capture of TPH1(104–394) was immobilized at 22°C until use. Biotinylated TPH1(104–394) with N-terminal His6-tag were grown in a bio-reactor (GE Healthcare). Biotinylation and capture of TPH1 (104–394) was immobilized on a fast desalting column (Thermo scientific #89849, Superdex SPX200/16/60; GE Healthcare), using MES 25 mM, pH 6, NaCl 100 mM, Glycerol 5%, Methionine 3 mM, TCEP 2 mM as elution buffer. For crystallization purposes, the protein was concentrated to 10 mg ml\(^{-1}\). The resulting protein was estimated to be >95% pure and homogeneous by SDS-PAGE and reverse phase HPLC. The identity of the protein was further confirmed by N-terminal sequencing and mass spectrometry (Q-Tof, Micromass, Waters). Structural location diagrams were generated using Molsoft ICMPro modeling tool. Protein sequence alignment was enabled by RCSB protein databank and EMBL Cluster Omega analysis.

**Mode of Inhibition Studies**

Mode of inhibition studies were performed in triplicate using the primary screen assay with varying concentrations of the substrate at fixed concentrations of inhibitor. For looking at the dependency of inhibition with tryptophan, BH4 was held at a fixed concentration of 10 µM and for looking at the dependency with BH4, tryptophan was held at a concentration of 10 µM. Reaction rates were monitored at fixed time points for up to 30 min and converted using a standard curve for 5-hydroxytryptophan. Slopes were subsequently calculated from the linear portions of the converted progress curves. The data was fitted globally to the equations describing competitive, non-competitive, mixed, and uncompetitive inhibition models (as described below) and best fit analysis was carried out using the Enzyme Kinetics module of SigmaPlot (V12.1).

**Novel Cell Assay Assessment of TPH1 Activity**

5-HT newly synthesized through TPH activity was assessed both in vitro and in vivo by addition of deuterium labeled substrate (deuterated tryptophan – TRP-d5) and subsequently generated deuterium labeled product (deuterated serotonin – 5HT-d4) (Figure 6A). BON (human pancreatic carcinoma) cell line was a gift from Dr. Courtney M. Townsend (University of Texas, Galveston, TX, USA) and cultured as previously described (Tran et al., 2004). Cells were seeded overnight in 96-well plates at 1.2 × 10\(^5\) cells per well in 200 µL growth media containing 1% FBS, and incubated at 37°C, 5% CO\(_2\). After 24 h, cell media was...
exchanged for 100 mL serum-free media. All reagents added to the cells in subsequent steps were diluted in serum-free media. Cells were treated with 25 µL of either compound or DMSO vehicle (1 % v/v) for 15 min at 37°C, 5% CO₂ and then treated with 25 µL 196 mM deuterated-tryptophan (Isotec, UK) for a further 2 h at 37°C, 5% CO₂. BON cell lysates were then prepared by removal of all media with subsequent addition of 250 mL HTAB. These lysates were further analyzed for D4-5-HT content by LCMS. Cell toxicity was also assessed in BON cells using a standard lactate dehydrogenase (LDH) assay according to instructions.

**Novel In Vivo Assessment of Pharmacokinetics/Harmcodynamics**

In vivo inhibition of newly synthesized 5-HT was assessed by dosing dogs either acutely or chronically with compound followed by injection of TRP-d₅ and subsequent 5-HT-d₄ (versus compound) measurement in blood. Six male beagle dogs, 2.5–7.0 years of age and 8.6–11.0 kg weight were used in this novel, non-lethal model. The study was performed as a three-way, three-period crossover design with two animals assigned to one of three groups in turn (A–C in Table 1).

Three hours after the first dose TRP-d₅ was injected subcutaneously at 50 mg kg⁻¹ as a suspension in aqueous 0.5% methyl cellulose : 0.5% (w/w) Tween 80. The mobile phase was aqueous 0.1% formic acid and the mobile phase B was methanol. The gradient program was as follows: 0–0.5 min 5% B, 0.5–1.0 min 5% to 95% B, 1.0–1.5 min 95%–5% B. The flow rate was 0.6 ml min⁻¹ and the sample injection volume was 5 µL. The mass spectrometer was operated in positive electrospray ionization mode and the analyte was detected using multiple reaction monitoring (MRM) transitions at m/z for 181 and 165 for incubation. The obtained unbound fraction fu was converted to the corresponding unbound fraction fu in undiluted plasma using the formula fu = 1 (D * (1 fu⁻¹ − 1 + 1 D⁻¹))⁻¹ where D is the dilution factor of 10.

### TABLE 1 | Canine model design.

| Group | Dosing: oral gavage, 0.5% MC : 0.5% (w/w) Tween 80, 4 mL kg⁻¹, 5 h intervals |
|-------|--------------------------------------------------------------------------------|
| A     | veh veh veh |
| B     | NVS-TPH120 veh veh |
| C     | NVS-TPH120 NVS-TPH120 NVS-TPH120 |

Three-way, three-period crossover design with two animals assigned to one of three dose groups in turn.

### TABLE 2 | Evolution of TPH1 inhibitors.

| Compound     | TPH-1 IC₅₀ (µM) SD | TPH-2 IC₅₀ (µM) SD |
|--------------|-------------------|-------------------|
| (1) pCPA     | 4.490 0.790       | 1.55 0.51         |
| (2) LP533401 | 0.103 0.038       | 0.032 0.006       |
| (3) NVS-TPH146| 0.271 0.040       | >10 n/a           |
| (4) NVS-TPH176| 0.174 0.038       | >10 n/a           |
| (5) NVS-TPH180| 0.039 0.018       | >10 n/a           |
| (6) NVS-TPH120| 0.021 0.009       | >10 n/a           |

Biochemical assay potencies on TPH-1 versus TPH-2. Examples 1–2 represent control orthosteric inhibitors. Examples 3–6 represent allosteric inhibitors of increasing TPH1 potency yet inactive on the TPH2 isoform.

The analyte peak area was quantified against the calibration curves established in the same analytical run using Analyst 1.6 software. The lower limit of quantification was established at 0.4 ng ml⁻¹.

For analysis of NVS-TPH120, samples were processed in a manner similar to that for 5HT-d₄. After protein precipitation with acetonitrile the supernatant (250 µl) was separated by centrifugation and further diluted with 50 µL of water. The processed samples were analyzed by LC-MS/MS in a Sciex API 4000 mass spectrometer coupled with a Waters Acquity UPLC. The chromatography was employed on a Waters Atlantis dC18 analytical column, 50 mm × 2 mm, 1.7 µm at 50°C. The mobile phase A was aqueous 0.1% formic acid and the mobile phase B was methanol. The gradient program was as follows: 0-0.5 min 5% B, 0.5-1.0 min 5% to 95% B, 1.0–1.5 min 95%–5% B. The flow rate was 0.6 ml min⁻¹ and the sample injection volume was 10 µL. The mass spectrometer was operated in negative electrospary ionization mode and the analyte was detected using MRM transitions at m/z for 429 > 385 for NVS-TPH120 and 309 > 215 for SDM. The analyte peak areas were quantified against the calibration curve established in the same analytical run using Analyst 1.6 software. The lower limit of quantification was established at 46 nM.

Plasma protein binding of NVS-TPH120 in dog plasma was measured by equilibrium dialysis using RED device (Thermo). Plasma was 10-fold diluted with water and spiked with NVS-TPH120 at 5 µM for incubation. The obtained unbound fraction fu was converted to the corresponding unbound fraction fu in undiluted plasma using the formula fu = 1 (D * (1 fu⁻¹ − 1 + 1 D⁻¹))⁻¹ where D is the dilution factor of 10.
FIGURE 1 | Identification of selectivity for TPH1 over TPH2. Compounds pCPA (A), LP533401 (B) and NVS-TPH146 (C) were pre-incubated with hTPH1 and hTPH2 enzymes for 15 min. Reactions were initiated with the addition of the substrates BH4 and Tryptophan. The reactions were quenched with the addition of 30% Sulfuric Acid at 30 min for hTPH1 and 60 min for hTPH2. The plates were read immediately with a PerkinElmer Envision reader (excitation = 280, emission = 535).

Animal Welfare and Ethics Statement

Animals used in these studies were housed and cared for throughout the experiment in accordance with Swiss Animal Welfare regulations (and in accordance to Directive 2010/63/EU) as they were performed in Switzerland. Study protocols were also assessed by the Novartis Institutes for Biomedical Research ethical review panel, to ensure conformation to the UK Animals (Scientific Procedures) Act 1986. Overnight fasting was applied before each experimental leg and food was returned 4 h after administration. All animals had free access to water before and throughout the experimental period. All procedures used were as humane as possible and complied with the recommendations of ARRIVE (Animal Research: Reporting In vivo Experiments).

Data Analysis and Statistical Procedures

Biochemical, cell and in vivo data were analyzed via Graphpad Prism (version 5; La Jolla, CA, USA). Biosensor data were evaluated using Biaevaluation software (GE Healthcare). Mechanism of action analytics were carried out using the Enzyme Kinetics module of SigmaPlot (V12.1). Pharmacokinetic parameters were calculated by non-compartmental method using Phoenix (Pharsight). In vitro cell data and in vivo data are presented as mean ±SEM. Ex vivo 5HT-d4 concentrations in the NVS-TPH120-treated group were normalized for those in the control group at each time point in the same session. One-way ANOVA was used for comparison between groups followed by Dunnett post hoc test which compared each of the NVS-TPH120 dosed groups with the control group – data represented as a percentage reduction.

Materials

Biochemical assay buffer reagents were purchased from Sigma–Aldrich (Poole, UK). Protein preparation reagents were purchased from Roche (Basel, Switzerland) and purification via Ni-NTA from Qiagen (Hilden, Germany). LDH cell toxicity assay was purchased from Pierce (Thermo Scientific). For Biacore experiments, L-Trp was purchased from Sigma–Aldrich (Poole, UK), BH2 was purchased from Schirks Laboratories (Jona, Switzerland). EZ-link Sulfo-NHS-LC-LC-Biotin was purchased from Fisher Scientific (Loughborough, UK). All other buffer reagents were purchased from Sigma–Aldrich (Poole, UK). Cell assay culture plates were purchased from Fisher Scientific (Loughborough, UK). Deuterated-tryptophan was purchased from Isotec (Southport, UK) and HTAB was purchased from Sigma-Aldrich (Poole, UK). L-tryptophan-2',4',5',6',7'-d5 (TRP-d5), methylcellulose, 1500 cP (MC), sulfadimethoxin from
Petrassi et al. Novel TPH1 Allosteric Inhibitory Site

FIGURE 2 | Surface Plasma Resonance (SPR) sensorgrams for the interaction of TPH1 with various ligands. Ligand (L-Trp – blue) and compound (LP533401 or NVS-TPH146 – red) were injected singularly or in combination (green). Comparison of the resulting equilibrium responses between the individual or simultaneous injection allowed the classification of their binding mode for LP533401 (A) and NVS-TPH146 (B).

Sigma–Aldrich (Poole, UK) and serotonin-α, α, β, β-d4 (5HT-d4) from Qmx Laboratories (Dunmow, UK) were used for in vivo studies.

RESULTS

Evolution in Potency and Selectivity of Allosteric TPH1 Inhibitors

Biochemical assays for TPH1 and TPH2 were used to assess increases in potency and selectivity for our emerging chemical series. Initially, dual TPH inhibitors were assessed for potency on both TPH1 and TPH2 in our assays. Relative IC₅₀ values of 4.49 and 1.55 mM were revealed for pCPA on TPH1 vs TPH2. Values for the Lexicon next generation TPH inhibitor (LP533401) were 0.103 and 0.032 mM on TPH1 vs. TPH2, respectively. Selectivity was first observed in the original high throughput screen hit NYS-TPH146, with TPH1 : 2 ratio of 0.271 : 10 mM (Table 2 and Figures 1A–C). Subsequent molecules (NVS-TPH176, -TPH180, and -TPH120) demonstrated incremental improvements in TPH1 potency (0.174, 0.039, and 0.021 mM) without erosion of TPH2 selectivity (> 10 mM) (Table 2). Early, less potent examples within the chemical series were sufficiently potent to demonstrate selectivity and the novel binding mode. The advances in potency achieved with TPH120 enabled later in vivo experiments.

Biophysical Characterization of the Allosteric Site

Do determine how and where the novel inhibitor class was binding, biophysical characterization of the site was performed. Surface plasma resonance (BiaCore) was used to confirm the allosteric versus orthosteric nature of NVS-TPH176 versus LP533401. The comparison of the resulting equilibrium responses between the individual or simultaneous injection of two ligands allows the classification of their binding mode. The obtained responses for the simultaneous injection of LP533401 and L-Trp is lower than the sum of individual injections. This suggests a competitive binding of both ligands (Figure 2A). The resulting equilibrium response for the simultaneous injection of NVS-TPH146 and L-Trp is comparable to the sum of the responses from single injections. This indicates that NVS-TPH146 and L-Trp bind simultaneously to TPH1 (Figure 2B). Comparable modes of inhibition for NVS-TPH146 were shown in studies co-injecting BH-2 co-factor and/or L-Trp (Supplementary Figure S1). The region of the novel allosteric site on TPH1 is shown in Figure 3A versus the orthosteric site where substrate, cofactor and Fe²⁺ bind. The residue interaction profile within the allosteric site is also revealed (Figure 3B). Sequence comparisons within the allosteric pocket show subtle differences between all isoforms (Supplementary Figure S2).

Kinetic Analysis of Inhibition

To better understand how the novel class of molecules antagonized TPH1, kinetic analysis was carried out. Detailed mechanism of inhibition studies were carried out with purified truncated protein, by varying both tryptophan and BH4 concentrations in the presence of fixed concentrations of inhibitor. When tryptophan concentration was varied in the presence of a fixed sub-saturating concentration of BH4, NVS-TPH180 showed a mixed mode of inhibition indicated by the convergence of lines close or just above the x-axis on the double reciprocal plot when fitted globally using a non-linear regression fit based on partial mixed mode of inhibition for a single substrate inhibitor. NVS-TPH180 also demonstrated a strong preference for the tryptophan bound complex as indicated by its alpha factor being 0.273 (Figure 4A). Competition studies with BH4, using a sub-saturating concentration of tryptophan (10 µM), also shows that NVS-TPH180 displays characteristics of a mixed partial inhibitor when fitted globally using a non-linear regression fit based on partial mixed mode of inhibition for a single substrate inhibitor. The alpha value of 1.1 is also indicative of a small (non-significant) preference towards the free enzyme (Figure 4B). Re-plot methods looking at the dependence of Vmax and Vmax/Km (data not shown) against inhibitor concentrations also show very similar hyperbolic relationships re-confiming that this compound behaves in a mixed/ non-competitive manner.
FIGURE 3 | Location of the novel TPH1 allosteric inhibitory site. The TPH1 protein is shown in gray ribbon with the catalytic site iron and cofactor shown. The allosteric site is indicated by the brown solvent accessible surface (A). The TPH1 protein residues that form close contacts with the allosteric ligands are shown in atom-type colored capped sticks with the site indicated by the transparent surface (B).

FIGURE 4 | Mechanism of action of allosteric inhibitors. Double reciprocal plots of initial velocities at various concentration of the inhibitor NVS-TPH180 with varying (A) tryptophan concentration at a fixed non-saturating concentration of BH4 (10 µM) and (B), varying BH4 at fixed non-saturating concentrations of tryptophan (10 µM). The inhibitor concentrations (I) used are as indicated in the graph and are represented in µM concentrations. Data is a mean ± SD from a single experiment, with each point in triplicate. Data was analyzed using Sigmaplot and fitted to a global fit analysis. Best fit analysis indicates a mixed partial inhibition with tryptophan with an α-value of 0.477 indicating a preference for the tryptophan bound complex.

with relative Ki values of 64 and 74 nM, and Km values of 13 and 11 µM, respectively, for both tryptophan and BH4 (Figure 4).

Cell Activity of Allosteric TPH1 Inhibitors
Whole cell activity of TPH1 inhibition was assessed using BON cells (human carcinoid cell line) within a newly designed in vitro assay where new synthesized 5-HT could be detected via the labeling of tryptophan substrate with deuterium. LP533401 registered an IC50 of 12.4 mM, whereas a value for pCPA could not be established. The early allosteric inhibitor NVS-TPH176 registered 27.2 mM, whereas a > 30-fold improvement in potency to 0.8 mM was observed with NVS-TPH120 (Figure 5). No impact on cell viability was detected for any compound up to 30 mM, assessed by LDH assay (Figure 5B).

Inhibition of De Novo Synthesis of Serotonin by NVS-TPH120 In Vivo
The degree to which in vitro inhibitory characteristics could be translated into animals, we developed an in vivo test
system. Serotonin has long elimination half-lives in blood which hampers early and robust detection of reduced rate of serotonin synthesis. Furthermore, sequence and biochemical potency species cross-reactivity analysis indicated a drop-off in alignment in rodents (Supplementary Figure S3). To overcome this challenge, we developed a novel in vitro mechanistic model using a deuterium-labeled tryptophan and monitoring its metabolic conversion to the deuterated serotonin which can be discriminated from native serotonin by LC-MS/MS analysis (Figure 6A). NVS-TPH120 was dosed to dogs orally once or three times with 5 h intervals between the doses. TRP-d5 was injected s.c. 3 h after the first dose. In the 1 × 100 mg kg⁻¹ group NVS-TPH120 blood concentrations reached a Cmax of 82 ± 38 µM at 2.3 ± 0.5 h (0.7 h before the TRP-d5 injection) followed by a monophasic decay at a mean elimination half-life of 7.7 ± 5.2 h (Figure 6C). Following 3 × 100 mg kg⁻¹ dosing of NVS-TPH120 a peak concentration of 109 ± 40 mM was reached at 11.0 ± 1.1 h. The 3 × 100 mg kg⁻¹ group achieved the mean AUC 3.3-fold higher than that after 1 × 100 mg kg⁻¹ dosing. The synthesis of 5HT-d4 was inhibited in a dose-dependent manner although significant efficacy was not observed until 29 h (Figure 6B). The lowered level of 5HT-d4 was sustained up to 104 h after the first dosing of NVS-TPH120 in the 3 × 100 mg/kg group. The in vitro IC₅₀ for the inhibition of dog TPH1 by NVS-TPH120 was scaled to the corresponding whole blood IC₅₀ taking into account plasma protein binding. Due to very high plasma protein binding (fu = 0.0018) the corrected IC₅₀ for blood was increased to 23 µM. The NVS-TPH120 concentration was maintained above the scaled IC₅₀ up to 12 h post compound dosing at 1 × 100 mg kg⁻¹ while the 3 × 100 mg kg⁻¹ treatment exceeded this blood concentration for up to 32 h (Figure 6D).

**DISCUSSION AND CONCLUSION**

Knockout studies have demonstrated the distribution of TPH isoforms in the body – TPH1 primarily expressed in the pineal gland and enterochromaffin cells of the gut, whereas TPH2 is restricted to neuronal cells (Cote et al., 2003; Walther et al., 2003; Patel et al., 2004). A breakthrough in pharmacologic inhibition of TPH was achieved with the discovery of molecules whose expanded pCPA core gained selectivity over related amino acid hydroxylases (phenylalanine and TH). Selectivity over TPH2 was effectively achieved through restricted distribution to the gut, including exclusion of enteric nerves (Shi et al., 2008; Margolis et al., 2014), providing both pre-clinical and clinical evidence for promising therapeutic options for gut-related disorders such as non-constipating irritable bowel syndrome (Brown et al., 2011; Kim et al., 2015). However, diseases in which pathogenesis is driven by TPH1 over expression, and subsequent 5-HT production, in peripheral tissues remain beyond the reach of these next generation inhibitors. Effective TPH1 inhibition beyond the gut requires pharmacologic selectivity over TPH2, and therefore a different chemical strategy entirely.

The TPH1-specific allosteric binding site described in these studies relies both on the robust, inventive nature of the assay systems used to investigate this novel biology, and on the availability of well characterized tool compounds for comparison. Literature characterization of pCPA and LP533401 have measured TPH1 activity at 250 and 0.7 mM IC₅₀ values, respectively, (Liu et al., 2008). These differ from the values reported here by approximately 50- and 7-fold, respectively, revealing a higher degree of sensitivity to inhibition within the biochemical assay system described in each study. A 17-fold drop in potency is observed in the BON cell assay for LP533401 (pCPA effect not measurable above 30 mM without apparent toxicity). These data contrast previous reports which suggest a greater potency in the rat mastocytoma line RBL-2H3 than that seen biochemically – surprising discrepancies which may be based upon differing species and/or undetected/mild cell toxicity (Liu et al., 2008). Early allosteric inhibitors showed a biochemical and cell profile superior to pCPA, yet inferior to LP533401. The inhibitory potential of the allosteric pocket was only revealed in later examples (e.g., NVS-TPH1120) which demonstrated 13- and 15-fold improvements over LP533401 in biochemical and cell potencies, respectively.

LP533401 was evolved from a common pCPA core, and thus the demonstration of an equivalent tryptophan substrate binding site could be anticipated and was confirmed in our BiaCore experiments (Cianchetta et al., 2010). The apparent chemical diversity of early inhibitor examples identified within our biochemical screen opened the possibility of a different binding mode. This hypothesis was supported by biochemical selectivity over TPH2 ->37-fold with the initial NVS-TPH146 compound, improving to >476-fold with NVS-TPH120. BiaCore studies...
FIGURE 6 | In vivo Inhibition of de novo synthesis of 5HT-d4 by NVS-TPH120. The study was conducted as a 3-way crossover design. Male beagle dogs received orally vehicle or NVS-TPH120 2 h before and 3 h and 8 h after subcutaneous injection of TRP-d5 at 50 mg kg⁻¹ (n = 6). Serially bled samples were analyzed by LC-MS/MS. (A) Metabolic pathway of TRP-d5 conversion to 5HT-d4. (B) Real values of blood 5-HT-d4 recovered from blood (baseline subtracted). (C) Blood 5HT-d4 levels % relative to the vehicle group. *P < 0.05; **P < 0.01. (D) Blood pharmacokinetic profiles of NVS-TPH120 (n = 6). AAAD: aromatic L-amino acid decarboxylase. The data are expressed as means ± SEM.

provided the first real evidence of a novel allosteric binding site, when NVS-TPH146 and tryptophan ligand/co-factor were able to bind simultaneously – data further confirmed by the resolution of co-crystals containing NVS-TPH176 (data not shown due to proprietary nature of compound structure). The location of the allosteric site suggests the potential to influence orthosteric binding from the opposite side of the protein, as indicated by a common sequence of alpha helix (Supplementary Figure S2).

Though there are subtle sequence differences in the allosteric site between each isoform, the exact mechanism by which selectivity for TPH1 is obtained with the novel inhibitors will likely require dynamic analytics to reveal. Mechanism of action experiments further demonstrated the lack of competitive binding to the substrate site, yet also suggested a preference for the tryptophan bound complex as indicated by its alpha factor being 0.273. This was reconfirmed by using re-plot methods in which we observed a larger titration in our Vmax versus inhibitor concentration plot as compared to our Vmax/Km plots - indicating that the inhibitor, although able to bind free enzyme at a low affinity, has a much higher preference and affinity for the substrate bound complex. This is consistent with X-ray data that shows the inhibitor binding to an area distal from the substrate binding site and suggests that this allosteric site becomes more accessible once the tryptophan binds. The alpha value of 1.1 for BH4 co-factor is also indicative of a small (non-significant) preference towards the free enzyme. Again, re-plot methods looking at the dependence of Vmax and Vmax/Km against inhibitor concentrations also show very similar hyperbolic relationships re-confirming that NVS-TPH180 behaves in a way entirely consistent with the X-ray observations that show a binding site distal to where BH4 resides. In both double-reciprocal plots, a beta value of less than one is generated, which indicates partial inhibition. However, it must be recognized that these assays are closed systems and as such one reason for apparent partiality could be due to the time for the right complex to form, to allow the inhibitor to exert its full affect. Once it forms the final complex, the inhibitor does not come off until both substrates come off, also contributing to the final affect. Further evidence of partiality is in vivo, where inhibition of newly synthesized 5-HT plateaus at approximately 50% (Figure 6).

Deuterium-labeled tryptophan was also used in vivo as a novel method by which specifically new synthesized 5-HT could be monitored. The system was successfully validated in rat, rabbit and dog using pCPA as a reference TPH inhibitor (data not shown). Comparative species homology of TPH1 decreases...
from human to rat – differences which impacted the degree to which allosteric molecules inhibited TPH1 – demonstrated by NVS-TPH120 within biochemical assays with different species proteins (Supplementary Figure S3). Comparable potency and efficacy was observed between human and dog proteins with NVS-TPH120 and thus further in vivo studies used dogs. TPH1 inhibited via the allosteric site showed significant efficacy, peaking at 50%, which was sustained up to 100 h post tryptophan injection. Significant inhibition was not observed until 29 h as reflected by the delay in the increase of blood 5HT-d4 levels.

The next steps in the evolution of this chemotype of allosteric inhibitors is the resolution of eroded rodent cross reactivity and high plasma protein binding. Improvements in these areas would provide a tool by which more direct assessment of efficacy upon 5-HT-mediated complex remodeling diseases of the periphery could be made – an example of which could be the rodent hypoxia/SUGEN model of PAH which demonstrates increased TPH1 expression and 5-HT production, and is also sensitive to pCPA inhibition (Ciucian et al., 2013; Thomas et al., 2013). Increased pulmonary artery endothelial cell (PAEC) TPH1 expression in PAH patients together with increased SERT expression in pulmonary artery smooth muscle cells (PASMC), may induce the hyperplasia central to PAH (Eddahibi et al., 2006). TPH1 knockout animals are protected from chronic hypoxia-induced pulmonary vascular remodeling and hypertension, although RV indices remain uninfluenced (Morecroft et al., 2007). PAEC:PASMC communication via 5-HT may not necessarily be paracrine, as demonstrated by co-culture studies investigating the role of 5-HT and TGFβ signaling through myoendothelial gap junctions to effect PASMC differentiation (Gairhe et al., 2012). The pathologic disease relevance of PAEC-derived 5-HT was further investigated in selective in vivo gene therapy studies. Adenoviral vectors targeted to PAECs (utilizing bispecific antibody to angiotensin-converting enzyme (ACE) as the selective targeting system) were used to deliver small hairpin Tph1 RNA sequences in rats. Hypoxic rats increased lung Tph1 expression leading to the development of PAH pathologies, both of which were attenuated by PAEC-Tph1 gene knockdown (Morecroft et al., 2012). A recent publication by Abid and colleagues suggested combined gut and lung inhibition with LP533401. It is conceivable that a profound reduction in the whole body burden of 5-HT may impact peripheral pathology as the primary source of 5-HT is the gut (>95% in healthy individuals) which is then stored in platelets in circulation (Walther et al., 2003). However, the hypothesized inhibition of lung TPH1 by LP533401 was based on lung measures containing 5-HT-devoid platelets. In addition, the surprising lack of pathway activation within the chronic hypoxia model used questions the validity of serotonin pathway involvement / analytics (Abid et al., 2012).

The clinical applicability of effective, selective TPH1 inhibition in peripheral tissues beyond the gut does not end with PAH. Recent transcriptome analysis has found an association between Bmpr1a deletion in mice and increased TPH1 expression in pancreatic islets, revealing a potentially important role for pancreatic 5-HT production in β-cell insulin production and glucose homeostasis (Jiang et al., 2015). These data are supported by studies in which Tph1-deficient mice fed a high-fat diet are protected from obesity, insulin resistance and nonalcoholic fatty liver disease while exhibiting greater energy expenditure by brown adipose tissue (Crane et al., 2015). Mechanistic evidence for 5-HT production, storage and release by T cells (particularly CD8+ T) is emerging which may bear relevance to an array of immune functional consequences in either health or disease (Chen et al., 2015). Furthermore, mast cell expression of TPH1, release of 5-HT and subsequent bronchoconstriction has been demonstrated in mice responding to allergen and IL-33, suggesting a pathologic role in the lung tissue of allergic asthmatics (Ahern, 2011; Sjöberg et al., 2015).

Thus, emerging evidence supports a role for TPH1 at the site of pathogenesis in complex remodeling, metabolic or immune diseases of peripheral tissues, and therefore necessitates a safe means of inhibition for effective therapy beyond the gut, yet without unwanted CNS effects. Here we describe a novel binding site on TPH1 to which the first molecules to achieve selectivity over TPH2 bind. The novel biologic systems generated to study these inhibitors also provide confidence that a major step forward has been taken in the development of a new class of safe peripheral serotonergic drugs.

**AUTHOR CONTRIBUTIONS**

CB, SB, A-MD, ND, MH, RF, PH, TK, PO, DR, CS, SH, MT, and RT made substantial contributions to the acquisition and analysis of data for the work. MP, NP, SW, MT made substantial contributions to the conception or design of the work. MP, RB, BC, GJ, NP, OS, JW, AW, NP, SW, MT made substantial contributions to the interpretation of data for the work. MT wrote the paper yet all authors were involved in drafting the work and revising it critically for important intellectual content. All authors approve the final version and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**FUNDING**

These investigations were funded by Novartis Institutes for Biomedical Research.

**ACKNOWLEDGMENT**

This work was funded by the Novartis Institutes for Biomedical Research. BON (human pancreatic carcinoid) cell line was a gift from Dr. Courtney M. Townsend (University of Texas, Galveston, TX, USA).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fphar.2017.00240/full#supplementary-material
FIGURE S1 | Kinetic analysis of inhibitors binding to TPH1 (A) Determination of the kinetic parameters of NVS-TPH146 binding to TPH1 (B) Determination of the kinetic parameters of LPS334101 binding to TPH1 (C) Equilibrium response for the individual versus simultaneous (blue) injection of BH4 (red) and L-Trp (green) is comparable to the sum of the responses from single injections. (D) Equilibrium response for the individual or simultaneous (blue) injection of NVS-TPH146 (green) or BH4 + L-Trp (red).

FIGURE S2 | Sequence alignment of amino acid hydroxylases TH, PH, TPH1, and TPH2. RCSB protein databank was used to obtain the human protein structures and sequences and EMBL for their Cluster Omega multi-sequence alignment. Regions of the orthosteric site are shown in blue and the agostic site in green, based upon residue interaction points (shown Figure 3).

FIGURE S3 | Percentage sequence homology table between species for TPH1 (A). Activity of NPS-TPH120 across the TPH1 assay using protein from different species (B). Reactions were initiated with the addition of the substrates BH4 and Tryptophan. The reactions were quenched with the addition of 30% Sulfuric Acid at 30 min for hTPH1 and 60 min for hTPH2. The plates were read immediately with a PerkinElmer Envision reader (excitation = 280, emission = 535).

REFERENCES

Abid, S., Houssaini, A., Chevarin, C., Marcos, E., Tissot, C. M., Gary-Bobo, G., et al. (2012). Inhibition of gut- and lung-derived serotonin attenuates pulmonary hypertension in mice. Am. J. Physiol. Lung. Cell Mol. Physiol. 303, L500–L508. doi: 10.1152/ajplung.00049.2012

Aherne, G. P. (2011). 5-HT and the immune system. Curr. Opin. Pharmacol. 11, 29–33. doi: 10.1016/j.coph.2011.02.004

Berger, M., Gray, J. A., and Roth, B. L. (2009). The expanded biology of serotonin. Curr. Chem. Genomics 213, 860–867. doi: 10.1111/apha.12470

Cianchetta, G., Stouch, T., Yu, W., Shi, Z. C., O’Connell, P. J., and Ahern, G. P. (2015). Equilibrium response for the individual or simultaneous (blue) injection of NVS-TPH146 (green) and release. Acta Physiol. 213, 860–867. doi: 10.1111/apha.12470

Coté, F., Stouch, T., Yu, W., Shi, Z. C., Li, L. W., Swanson, R. V., et al. (2010). Mechanism of inhibition of novel tryptophan hydroxylase inhibitors revealed by co-crystal structures and kinetic analysis. Curr. Chem. Genomics 4, 19–26. doi: 10.2174/1875397301004010019

Ciucan, L., Husey, M. J., Burton, V., Good, R., Duggan, N., Beach, S., et al. (2013). Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of TPH1 (A).

Chen, Y., Leon-Ponce, M., Pingle, S. C., O’Connell, P. J., and Ahern, G. P. (2015). T lymphocytes possess the machinery for 5-HT synthesis, storage, degradation and release. Acta Physiol. 213, 860–867. doi: 10.1111/apha.12470

Cianchetta, G., Stouch, T., Yu, W., Shi, Z. C., Tari, A. L., Wang, H., et al. (2014). Sumatriptan (all routes of administration) for acute migraine attacks in adults–overview of Cochrane reviews. Cochrane Database Syst. Rev. 5, CD009108. doi: 10.1002/14651858.CD009108.pub2

Dartevelle, P., et al. (2006). Cross talk between endothelial and smooth muscle cell differentiation. Mol. Pharmacol. 69, 1104–1118. doi: 10.1124/mol.2005.101278

Engelman, K., Lovenberg, W., and Sjoerdsmas, A. (1967). Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome. N. Engl. J. Med. 277, 1103–1108. doi: 10.1056/NEJM196711232772101

Frishman, W. H., Huberfeld, S., Okin, S., Wang, Y. H., Kumar, A., and Shareef, B. (1995). Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J. Clin. Pharmacol. 35, 541–572. doi: 10.1002/jpet.1860440103.x

Gairhe, S., Bauer, N. N., Gabb, S. A., and McMurtry, I. F. (2012). Serotonin passes through myoendothelial gap junctions to promote pulmonary arterial smooth muscle cell differentiation. Am. J. Physiol. Lung. Cell Mol. Physiol. 303, L676–L777. doi: 10.1152/ajplung.00183.2012

Jiang, F. X., Mishina, Y., Baten, A., Morahan, G., and Harrison, L. C. (2015). Transcriptome of pancreas-specific BMP1A-deleted islets links to TPH1/C05-HT axis. Biof Open 4, 1016–1023. doi: 10.1016/j.biope.2015.01.005

Kim, J. J., Wang, H., Hwang, D. J., Zambrovicz, B., Yang, Q. M., and Khan, W. I. (2015). Blocking peripheral serotonin synthesis by Telotristat Etiprate (XLX1032/LX1606) reduces severity of both chemical- and infection-induced intestinal inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 309, G454–G465. doi: 10.1152/ajpgi.00299.2014

Kulke, M. H., O’Dorioso, T., Phan, A., Bergland, E., Law, L., Banks, P., et al. (2014). Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr. Relat. Cancer 21, 705–714. doi: 10.1530/ERC-14-0173

Liu, Q., Yang, Q., Sun, W., Vogel, P., Heydorn, W., Yu, X. Q., et al. (2008). Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J. Pharmacol. Exp. Ther. 325, 47–55. doi: 10.1111/j.1749-6632.2007.003266

Lovenberg, W., Jequier, E., and Sjoerdsmas, A. (1967). Tryptophan hydroxylation: measurement in pineal gland, brain stem, and carcinoid tumor. Science 155, 217–219. doi: 10.1126/science.153.3759.217

Margolis, K. G., Stevanovic, K., Li, Z., Yang, Q. M., Oravec, T., Zambrovicz, B., et al. (2014). Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. Gut 63, 928–937. doi: 10.1136/gutjnl-2013-304901

Morecroft, I., Dempsey, B., Bader, M., Walther, D. J., Kotnik, K., Loughlin, L., et al. (2007). Effect of tryptophan hydroxylation deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 49, 232–236. doi: 10.1161/01.HYP.0000252210.58849.79

Morecroft, I., White, K., Caruso, P., Nilsen, M., Loughlin, L., Alba, R., et al. (2012). Gene therapy by targeted adenosinoremediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension. Mol. Ther. 20, 1516–1528. doi: 10.1038/mt.2012.70

Patel, P. D., Pontrello, C., and Burke, S. (2004). Robust and tissue-specific expression of TPH2 versus TPH1 in rat raphe and pineal gland. Biol. Psychiatry 55, 428–433. doi: 10.1016/j.biopsych.2003.09.002

Shah, S. J., Gomberg-Maitland, M., Thennappan, T., and Rich, S. (2009). Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. Chest 136, 694–700. doi: 10.1378/chest.08-2823

Shi, Z. C., Devasagayaraj, A., Gu, K., Jin, H., Marinelli, B., Samala, L., et al. (2008). Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders. J. Med. Chem. 51, 3684–3687. doi: 10.1021/jm800338j

Sjoberg, I. C., Gregory, J. A., Dahlen, S. E., Nilsson, G. P., and Adner, M. (2015). Interleukin-33 exacerbates allergic bronchoconstriction in the mice via activation of mast cells. Allergy 70, 514–521. doi: 10.1111/all.12590

Frontiers in Pharmacology | www.frontiersin.org

May 2017 | Volume 8 | Article 240

11

Petrassi et al. Novel TPH1 Allosteric Inhibitory Site
Petrassi et al. Novel TPH1 Allosteric Inhibitory Site

Stahl, S. M., Lee-Zimmerman, C., Cartwright, S., and Morrissette, D. A. (2013). Serotonergic drugs for depression and beyond. *Curr. Drug Targets* 14, 578–585. doi: 10.2174/1389450111314050007

Thomas, M., Ciuclan, L., Hussey, M. J., and Press, N. J. (2013). Targeting the serotonin pathway for the treatment of pulmonary arterial hypertension. *Pharmacol. Ther.* 138, 409–417. doi: 10.1016/j.pharmthera.2013.02.002

Tomillero, A., and Moral, M. A. (2008). Gateways to clinical trials. *Methods Find. Exp. Clin. Pharmacol.* 30, 543–588.

Tran, V. S., Marion-Audibert, A. M., Karatekin, E., Huet, S., Cribier, S., Guillaumie, K., et al. (2004). Serotonin secretion by human carcinoid BON cells. *Ann. N. Y. Acad. Sci.* 1014, 179–188. doi: 10.1196/annals.1294.019

Walther, D. J., and Bader, M. (2003). A unique central tryptophan hydroxylase isoform. *Biochem. Pharmacol.* 66, 1673–1680. doi: 10.1016/S0006-2952(03)00356-2

Walther, D. J., Peter, J. U., Bashammakh, S., Hortnagl, H., Voits, M., Fink, H., et al. (2003). Synthesis of serotonin by a second tryptophan hydroxylase isoform. *Science* 299, 76. doi: 10.1126/science.1078197

Werner, F. M., and Covenas, R. (2014). Safety of antipsychotic drugs: focus on therapeutic and adverse effects. *Expert Opin. Drug Saf.* 13, 1031–1042. doi: 10.1517/14740338.2014.935761

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The research conducted details preclinical drug discovery activities which were ultimately aimed at generating a novel therapeutic for the treatment of remodeling conditions dependent on serotonin dysregulation (e.g., pulmonary arterial hypertension). This research was funded by Novartis Institutes for Biomedical Research and formed part of a strategic initiative to develop an effective medicine, thereby associated/aligned with commercial needs.

Copyright © 2017 Petrassi, Barber, Be, Beach, Cox, D’Souza, Duggan, Hussey, Fox, Hunt, Jarai, Kouka, Oakley, Patel, Press, Rowlands, Scheufler, Schmidt, Srinivas, Turner, Turner, Westwick, Wolfreys, Pathan, Watson and Thomas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.